🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

GSK shares jump after $2.2 bln settlement for 80,000 Zantac lawsuits

Published 10/10/2024, 08:48
© Reuters
GSK
-
GSK
-

Investing.com -- Shares of GSK plc (OTC:GLAXF) (LON:GSK) jumped on Thursday after the company said that it has reached settlements regarding about 80,000 lawsuits related to its Zantac product in the United States. 

At 3:46 am (0746 GMT), GSK was trading 6.6% higher at £1,554.23.

The company has agreed to resolve 93% of the product liability cases pending in U.S. state courts for a total payment of up to $2.2 billion. 

This comes as GSK continues to face litigation over claims that Zantac may be linked to cancer, although the company maintains that there is no reliable scientific evidence supporting these allegations.

The settlements, which were reached with ten plaintiff firms representing the majority of the cases, are expected to be fully implemented by the end of the first half of 2025. 

The plaintiff firms have recommended to their clients that they accept the terms of the settlement, reflecting a consensus among those involved in the litigation.

“GSK also confirms that it has reached an agreement in principle to pay a total of $70 million to resolve the Zantac qui tam complaint previously filed by Valisure,” the company said in a statement,

This agreement is pending final approval from the Department of Justice.

While GSK has settled the lawsuits, the company has not admitted any liability in either the state court settlements or the qui tam settlement. 

The company asserts that the settlements are in the best interests of its long-term strategy and financial stability, helping to eliminate uncertainties associated with ongoing litigation.

To account for these settlements, GSK plans to recognize an incremental charge of £1.8 billion in its financial results for the third quarter of 2024.

This charge will cover the costs associated with the settlements and the remaining 7% of pending product liability cases. 

However, GSK assures investors that these expenses will be funded through existing resources and will not alter its growth agenda or research and development investment plans.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.